Drugdocs | Recarbrio

Recarbrio

Chemical Name	imipenem, cilastatin, and relebactam
Dosage Form	Injection (intravenous; 1.25 g/vial)
Drug Class	Multiple
System	Multiple
Company	Merck & Co.
Approval Year	2019

Indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Indicated in patients 18 years of age and older for the treatment of complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options.
Indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options.

Document Title	Year	Source
Recarbrio (imipenem, cilastatin, and relebactam) Prescribing Information.	2022	Merck & Co. Inc., Rahway, NJ

Document Title	Year	Source
Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.	2023	International Journal of Antimicrobial Agents
Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection.	2020	Medicine
Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections: a Bayesian network meta-analysis of randomized clinical trials.	2019	Medicine

Document Title	Year	Source
IDSA guidance on the treatment of antimicrobial-resistant gram-negative Infections: version 1.0.	2022	Infectious Diseases Society of America

Drug updated on 6/26/2023